SNM summit advances molecular imaging

Advisors from the U.S. Food and Drug Administration (FDA) provided a regulatory framework for developing nanotechnology and targeted radiopharmaceuticals at this week's SNM Nanomedicine and Molecular Imaging Summit in Albuquerque, NM.

Working in concert with SNM and other stakeholders, the FDA is seeking to educate imaging physicians, researchers, and other healthcare professionals about the regulatory requirements for novel techniques and regulatory pathways.

The fourth annual SNM summit also explored ways in which molecular imaging and therapy currently use nanotechnology, as well as how these methods can facilitate advancements in the understanding and proper management of nanomaterials both for the environment and human health.

At another session, Dr. John Frangioni, Ph.D., associate professor of medicine and radiology, and Hak Soo Choi, Ph.D., instructor in medicine at Harvard Medical School's Beth Israel Deaconess Medical Center in Boston, spoke about design considerations for nanoparticles that interact with the body.

Their presentations reviewed recent developments in the field and discussed how this new understanding of nanoparticles might guide future studies in air pollution, drug delivery, and carcinogenesis.

In addition, Dr. King Li, chair of the department of radiology at the Methodist Hospital Research Institute in Houston, gave participants the opportunity to discuss how nanotechnology can be used to diagnose and treat disease.

Related Reading

SNM supports SGR rate fix, December 23, 2009

SNM contests proposed CMS payment rules, November 6, 2009

SNM urges CARE bill passage, September 30, 2009

SNM launches master's degree program, September 28, 2009

SNM: Nuclear medicine tests being postponed, September 9, 2009

Copyright © 2010

Page 1 of 436
Next Page